Article citationsMore>>

Jimenez-Cauhe, J., Saceda-Corralo, D., Rodrigues-Barata, R., Hermosa-Gelbard, A., Moreno-Arrones, O.M., Fernandez-Nieto, D., et al. (2019) Effectiveness and Safety of Low-Dose Oral Minoxidil in Male Androgenetic Alopecia. Journal of the American Academy of Dermatology, 81, 648-649.
https://doi.org/10.1016/j.jaad.2019.04.054

has been cited by the following article:

• TITLE: The Pathogenesis and Treatment Progress of Androgenic Alopecia

  AUTHORS: Huijuan Fan, Faqing Huang

  KEYWORDS: Androgen Alopecia, Pathogenesis, Gene Expression, Signal Transduction, Treatment Progress, Targeted Therapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.6, June 20, 2024

  ABSTRACT: Androgenic alopecia, also known as seborrheic alopecia, is the most common hair loss disorder in dermatology clinics, mainly characterized by hair follicle miniaturization and progressive hair loss. The etiology and pathogenesis of androgenic alopecia are not clear, but may be related to heredity and androgen metabolism. Currently, minoxidil and finasteride are the only two drugs approved by the U.S. Food and Drug Administration (FDA) for AGA treatment, other treatments include oral minoxidil, hair transplantation, low energy laser therapy (LLLT), platelet-rich plasma (PRP), Chinese medicine microneedles, and combination therapy. With the development of medicine and science, we have ushered in the era of biologics and targeted therapy. In recent years, a variety of signaling pathways for androgenic alopecia have been found, which may provide a basis for targeted therapy for androgenic alopecia.